
Biosimilars: Unlocking access, closing the cost divide
Newsletters and Deep Dive digital magazine
Apogee shares have spiked on data showing strong efficacy with its atopic dermatitis drug and the potential for dosing just two to four times a year.
Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems.
Claus Zieler, chief commercial and medical affairs officer & member of the Executive Committee at Astellas Pharma, spoke with pharmaphorum at ASCO25.
Developments in the oncology space in 2024 brought hope to both industry and patients.
The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference
Axtria’s flagship event is almost here! Axtria Ignite 2025 is taking place 4th to 5th June at the Princeton Marriott at Forrestal in New Jersey. This